801233-77-2

Upstream product

• 104-94-9 4-methoxy-aniline 
• 801233-48-7 2-(3,5-difluoro-4-methoxyphenyl)-6-methoxyquinolin-4-ol 
• 868708-06-9 3-(3,5-difluoro-4-methoxy-phenyl)-3-oxo-propionic acid ethyl ester 
• 801233-40-9 methyl (3,5-difluoro-4-methoxybenzoyl)acetate 
• 801233-62-5 4-bromo-2-(3,5-difluoro-4-methoxyphenyl)-6-methoxyquinoline 
• 170570-79-3 1-(3,5-difluoro-4-methoxy-phenyl)ethanone 

Relevant academic research and scientific papers

PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREVENTING, TREATING, OR INHIBITING INFLAMMATORY DISEASES, DISORDERS, OR CONDITIONS OF THE SKIN, AND DISEASES, DISORDERS, OR CONDITIONS ASSOCIATED WITH COLLAGEN DEPLETION

The present invention provides compositions and methods for preventing, treating, or inhibiting inflammatory diseases, disorders, or conditions of the skin, and diseases, disorders, or conditions associated with collagen depletion using one or more estrogenic agents.

ERβ ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives

A new class of estrogen receptor β (ERβ) ligands based on the 2-phenylquinoline scaffold was prepared. Several analogues with C4 substitution displayed high affinity (3-5 nM) and significant selectivity (up to 83-fold) for ERβ. The best compound, 13b, was profiled as a selective partial agonist for ERβ at 1 μM in a cell-based transcriptional assay. Uterine weight bioassay of 13b indicated no activation of ERα in vivo.

PHENYL GUINOLINES AND THEIR USE AS ESTROGEN RECEPTOR MODULATORS

This invention provides estrogen receptor modulators of formula: (I), having the structure wherein, R1, R2, R3, R4, R5 and R6 are as defined in the specification, or a N-oxide thereof or a pharmaceutically acceptable salt thereof or a prodrug thereof.